In Short Order, Merck And Stallergenes File BLAs For New Allergy Immunotherapies
This article was originally published in The Pink Sheet Daily
Executive Summary
Both Merck and French biotech Stallergenes have filed BLAs with FDA for approval of their respective grass allergy immunotherapies.